Cancer immunotherapy using the Fusion gene of Sendai virus

  title={Cancer immunotherapy using the Fusion gene of Sendai virus},
  author={Jiayu A. Tai and Chin Yang Chang and Tomoyuki Nishikawa and Yasufumi Kaneda},
  journal={Cancer Gene Therapy},
Inactivated Sendai virus particle (or hemagglutinating virus of Japan envelope; HVJ-E) has been previously reported to possess antitumour properties that activate antitumour immunity. Two glycoproteins, fusion (F) and hemagglutinin-neuraminidase (HN), are present on the surface of HVJ-E. HN is necessary for binding to receptors such as acidic gangliosides, and F induces membrane fusion by associating with membrane lipids. We previously reported that liposomes reconstituted with F but not HN… 
1 Citations
iPSC screening for drug repurposing identifies anti‐RNA virus agents modulating host cell susceptibility
It is demonstrated that SERMs blocked entry steps of SARS‐CoV‐2 into host cells, suggesting that the identified FDA‐approved drugs can modulate host cell susceptibility against RNA viruses.


Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production
IL-12–conjugated HVJ-E is a promising tool for the treatment of cancers, including lung metastasis by inducing local production of IFN-γ in the lungs and generating large numbers of melanoma-specific CTLs.
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.
Development of tissue-targeting hemagglutinating virus of Japan envelope vector for successful delivery of therapeutic gene to mouse skin.
A novel tissue-targeting HVJ-E could be used to successfully target epidermal keratinocytes both in vitro and in vivo, and its application in gene therapy of a mouse model of genetic skin disease is reported.
An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis.
It is discovered that the "copy-back" type of defective-interfering (DI) particles that exist in the Cantell strain of HVJ induced the human PC3 prostate cancer cell death more effectively than the Sendai/52 strain or Cantell strains, which contain fewer DI particles.
Systemic administration of platelets incorporating inactivated Sendai virus eradicates melanoma in mice.
A platelet vector incorporating viral particles, a Trojan horse for cancer treatment, will provide a new approach for cancer therapy using oncolytic viruses.
Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system.
HVJ envelope vector will be useful for both ex vivo and in vivo gene therapy experiments, and efficiency of gene transfer was greatly enhanced by protamine sulfate and centrifugation.
Sendai virus-induced cell fusion.
  • Y. Okada
  • Biology
    Methods in enzymology
  • 1993
Antitumor Activity Mediated by CpG: The Route of Administration is Critical
Evidence is provided that the route of CpG administration is a critical factor in mediating antitumor activity and effectively promotes the migration, activation and function of immune cells, ultimately leading to improved tumor control.
Sendai virus internal fusion peptide: structural and functional characterization and a plausible mode of viral entry inhibition.
It is found that SV-201 and its elongated form, SV-197, are highly potent in inducing fusion of the highly stable large unilamellar vesicles composed of egg phosphatidylcholine, a property found only in an extended version of the HIV-1 fusion peptide.